An ergonomics assessment of the physical risk factors in the workplace is instrumental in predicting and preventing musculoskeletal disorders (MSDs). Using Artificial Intelligence (AI) has become increasingly popular for ergonomics assessments because of the time savings and improved accuracy. However, most of the effort in this area starts and ends with producing risk scores, without providing guidance to reduce the risk. This paper proposes a holistic job improvement process that performs automatic root cause analysis and control recommendations for reducing MSD risk. We apply deep learning-based Natural Language Processing (NLP) techniques such as Part of Speech (PoS) tagging and dependency parsing on textual descriptions of the physical actions performed in the job (e.g. pushing) along with the object (e.g. cart) being acted upon. The action-object inferences provide the entry point to an expert-based Machine Learning (ML) system that automatically identifies the targeted work-related causes (e.g. cart movement forces are too high, due to caster size too small) of the identified MSD risk (e.g. excessive shoulder forces). The proposed framework utilises the root causes identified to recommend control strategies (e.g. provide larger diameter casters, minimum diameter 8" or 203 mm) most likely to mitigate risk, resulting in a more efficient and effective job improvement process.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00140139.2024.2394510DOI Listing

Publication Analysis

Top Keywords

msd risk
12
risk
8
root analysis
8
job improvement
8
improvement process
8
nlp-based ergonomics
4
ergonomics msd
4
risk root
4
analysis risk
4
risk controls
4

Similar Publications

Background: Proenkephalin A 119-159 (penKid) is a novel blood biomarker for real-time assessment of kidney function and was found to be independently associated with worsening kidney function and mortality. A novel penKid-based estimated glomerular filtration rate equation (eGFR), outperforms current creatinine-based eGFR equations in predicting iohexol or iothalamate plasma clearance-based measured GFR. In this study, we aimed to evaluate the predictive value of penKid and eGFR for all-cause mortality in stable patients at high cardiovascular risk.

View Article and Find Full Text PDF

Anamorelin, a highly selective ghrelin receptor agonist, enhances appetite and increases lean body mass in patients with cancer cachexia. However, the predictors of its therapeutic effectiveness are uncertain. This study aimed to investigate the association between the Glasgow prognostic score (GPS), used for classifying the severity of cancer cachexia, the therapeutic effectiveness of anamorelin, and the feasibility of early treatment based on cancer types.

View Article and Find Full Text PDF

Major ABO Incompatibility in Non-Myeloablative Hematopoietic Stem Cell Transplant for Sickle Cell Disease-Not an Insurmountable Obstacle.

Pediatr Blood Cancer

January 2025

Blood and Marrow Transplant/Cellular Therapy Program, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

With advances in conditioning strategies and graft-versus-host disease (GvHD) prevention, hematopoietic stem cell transplantation (HSCT) is a safe, curative treatment option for pediatric patients with sickle cell disease (SCD). However, donor options have been limited in non-myeloablative matched sibling donor (MSD) setting by excluding recipients with major ABO blood group incompatible donors due to concern of the risk of significant complications such as pure red cell aplasia (PRCA). We present three cases of successful HSCT with major ABO incompatibility with their donors, and discuss strategies to safely expand the donor pool to include these donors.

View Article and Find Full Text PDF

Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer.

Clin Breast Cancer

December 2024

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address:

Introduction: Adjuvant abemaciclib was recently approved in high-risk early breast cancer, leading to an increase in oncology resource utilisation. We thus developed a regional, remote monitoring clinical service. The set-up, delivery processes and outcomes from the first 6 months' consecutive patients are presented.

View Article and Find Full Text PDF

Introduction: Several cardiovascular outcome trials have been conducted to assess the cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on cardiorenal outcomes in patients with type-2 diabetes (T2D). However, the strict requirements of randomised controlled trials to avoid most confounding factors are at the expense of external validity. Using national real-world data, we aimed to evaluate the effectiveness of GLP-1RAs in association with metformin especially on cardiovascular events, hospitalisation for heart failure and all-cause death in comparison with other diabetes treatment schemes using dipeptidyl peptidase IV inhibitors, sulfonylureas/glinides or insulin also associated with metformin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!